104107-22-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-Bromo-2-methyl-1-indanone is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new compounds with therapeutic or pesticidal properties.
Used in Antimicrobial Agent Development:
In the field of antimicrobial research, 5-Bromo-2-methyl-1-indanone is utilized as a potential candidate for the development of new antimicrobial agents due to its inherent antibacterial and antifungal properties, which can be harnessed to combat resistant strains of pathogens.
Used as a Reagent in Organic Synthesis:
5-Bromo-2-methyl-1-indanone is employed as a reagent in organic synthesis, specifically for the preparation of indanone derivatives, which are important in the creation of a variety of chemical compounds.
Used in Medicinal Chemistry and Drug Discovery:
As a versatile building block, 5-Bromo-2-methyl-1-indanone is used in medicinal chemistry and drug discovery for the synthesis of biologically active compounds, which may lead to the development of new therapeutic agents and treatments for various diseases and conditions.

Upstream product

• 34598-49-7 5-Bromo-1-indanone 
• 628732-08-1 methyl 5-bromo-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 
• 50-00-0 formaldehyd 
• 10342-83-3 4'-Bromopropiophenone 

Relevant academic research and scientific papers

Ring-expansion approaches for the total synthesis of salimabromide

We describe the evolution of a synthetic strategy for the construction of the marine polyketide salimabromide. Combining a bicyclo[3.1.0]hexan-2-one ring-expansion to build up a functionalized naphthalene and an unprecedented rearrangement/cyclization cascade, enabled synthesis of a dearomatized tricyclic subunit of the target compound. Alternatively, an intramolecular keteniminium [2 + 2]-cycloaddition and subsequent Baeyer–Villiger ring-expansion gave access to the sterically encumbered architecture of salimabromide. Sequential oxidation of the carbon framework finally enabled the total synthesis of this unusual natural product.

Aromatic tetracyclic compounds of the retinoid type method for preparing and use

The invention concerns aromatic tetralcyclic compounds of the retinoid type of general formula (I). The invention also concerns the method for preparing them and the pharmaceutical compositions containing at least one of said compounds.

Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indenopyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tetrahydrobenzocinnolin-3(2H)-ones

Novel 7-substituted-4,4a-dihydro-4a-methyl-5H-indenopyridazin-3-ones and 8-substituted-4a-methyl-benzocinnolin-3-ones have been synthesized and their PDE III inhibitory, inotropic and vasodilator potencies compared with those of their normethyl analogues and their bicyclic 4,5-dihydro-6-phenylpyridazinone analogues.The structure-activity relationships of the tricyclic pyridazinones differ from those of bicyclic pyridazinones mainly in respect of the effect of introducing the methyl group into the pyridazinone ring.Whilst in the4,5-dihydro-6-phenylpyridazin-3(2H)-ones, introduction of a 5-methyl group has been widely reported to lead to compounds of significantly greater potency, the novel tricyclic 4a-methylpyridazinones showed similar levels of inotropic, vasodilator and PDE III inhibitory potency to their normethyl analogues.Possible reasons for this difference in behaviour are discussed.

Tricyclic pyridazinone compounds

This invention relates to tricyclic pyridazinone compounds, pharmaceutical compositions containing the compounds, and a method of stimulating cardiac activity in a mammal by administering an effective amount of the compound. A compound of the invention is